David founded Janux in 2017 to develop tumor-specific cancer therapeutics aimed at improving patient safety and efficacy. David has more than 25 years of executive management, company creation, partnering, disease, and drug development experience.
Mr. Dobmeier is a biotechnology executive and board member with more than 20 years of experience. He was president and CEO of Chinook Therapeutics and Silverback Therapeutics and spent 16 years at Seattle Genetics, including as chief operating officer.
Ms. Hernday served as chief business officer and an Executive Committee member at Seagen until its 2023 acquisition by Pfizer for $43 billion. She joined Seagen in 2011, led its business development team, and spent 16 years at Amgen.
Janux is developing novel immunotherapies to stimulate the immune system without causing systemic safety issues to fight cancer and autoimmune diseases.
With its headquarters in San Diego, CA, Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel T cell immunotherapies.
Janux is developing novel immunotherapies that selectively modulate T cells to fight cancer and autoimmune diseases without causing systemic safety issues.
